Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Correction: Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients.

Sardaro A, Saito K, Nakayama E, Valmori D.

PLoS One. 2016 Jul 28;11(7):e0160538. doi: 10.1371/journal.pone.0160538. eCollection 2016.

2.

Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer.

Valmori D, Ayyoub M.

Oncoimmunology. 2014 Oct 29;5(4):e947175. eCollection 2016 Apr.

3.

Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients.

Saito K, Nakayama E, Valmori D.

PLoS One. 2016 Mar 3;11(3):e0150623. doi: 10.1371/journal.pone.0150623. eCollection 2016. Erratum in: PLoS One. 2016;11(7):e0160538.

4.

Modulation of Cytokine Secretion Allows CD4 T Cells Secreting IL-10 and IL-17 to Simultaneously Participate in Maintaining Tolerance and Immunity.

Saito K, Pignon P, Ayyoub M, Valmori D.

PLoS One. 2015 Dec 28;10(12):e0145788. doi: 10.1371/journal.pone.0145788. eCollection 2015.

5.
6.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

7.

Differential expression of the immunosuppressive enzyme IL4I1 in human induced Aiolos+, but not natural Helios+, FOXP3+ Treg cells.

Scarlata CM, Celse C, Pignon P, Ayyoub M, Valmori D.

Eur J Immunol. 2015 Feb;45(2):474-9. doi: 10.1002/eji.201444897. Epub 2015 Jan 16.

8.

Comment on "differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors".

Ayyoub M, Valmori D.

J Immunol. 2014 Oct 1;193(7):3181. doi: 10.4049/jimmunol.1401944. No abstract available.

9.

Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS.

Ayyoub M, Memeo L, Alvarez-Fernández E, Colarossi C, Costanzo R, Aiello E, Martinetti D, Valmori D.

Cancer Immunol Res. 2014 Oct;2(10):943-8. doi: 10.1158/2326-6066.CIR-13-0211. Epub 2014 May 27.

10.

CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated Treg.

Ayyoub M, Pignon P, Classe JM, Odunsi K, Valmori D.

Cancer Immunol Res. 2013 Nov;1(5):303-8. doi: 10.1158/2326-6066.CIR-13-0062-T. Epub 2013 Aug 19.

11.

Expression of MAGE-A3/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survival.

Ayyoub M, Scarlata CM, Hamaï A, Pignon P, Valmori D.

J Immunother. 2014 Feb-Mar;37(2):73-6. doi: 10.1097/CJI.0000000000000013.

PMID:
24509169
12.

Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering.

Romero AI, Chaput N, Poirier-Colame V, Rusakiewicz S, Jacquelot N, Chaba K, Mortier E, Jacques Y, Caillat-Zucman S, Flament C, Caignard A, Messaoudene M, Aupérin A, Vielh P, Dessen P, Porta C, Mateus C, Ayyoub M, Valmori D, Eggermont A, Robert C, Zitvogel L.

Cancer Res. 2014 Jan 1;74(1):68-80. doi: 10.1158/0008-5472.CAN-13-1186. Epub 2013 Nov 6.

13.

Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1β by downregulating their suppressor functions.

Raffin C, Pignon P, Celse C, Debien E, Valmori D, Ayyoub M.

J Immunol. 2013 Nov 1;191(9):4619-27. doi: 10.4049/jimmunol.1301378. Epub 2013 Sep 25.

14.

Comment on "helios+ and helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans".

Ayyoub M, Raffin C, Valmori D.

J Immunol. 2013 May 1;190(9):4439-40. doi: 10.4049/jimmunol.1390018. No abstract available.

15.

MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.

Poli C, Raffin C, Dojcinovic D, Luescher I, Ayyoub M, Valmori D.

Haematologica. 2013 Feb;98(2):316-22. doi: 10.3324/haematol.2012.071712. Epub 2012 Aug 8.

16.

CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity.

Redjimi N, Raffin C, Raimbaud I, Pignon P, Matsuzaki J, Odunsi K, Valmori D, Ayyoub M.

Cancer Res. 2012 Sep 1;72(17):4351-60. doi: 10.1158/0008-5472.CAN-12-0579. Epub 2012 Jul 12.

17.

Generation of Th17 from human naive CD4+ T cells preferentially occurs from FOXP3+ Tregs upon costimulation via CD28 or CD5.

Ayyoub M, Raffin C, Valmori D.

Blood. 2012 May 17;119(20):4810-2; author reply 4812-3. doi: 10.1182/blood-2012-02-409722. No abstract available.

18.

Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-γ-secreting cells as they differentiate into effector T cells in vivo.

Hamaï A, Pignon P, Raimbaud I, Duperrier-Amouriaux K, Senellart H, Hiret S, Douillard JY, Bennouna J, Ayyoub M, Valmori D.

Cancer Res. 2012 Mar 1;72(5):1059-63. doi: 10.1158/0008-5472.CAN-11-3432. Epub 2012 Jan 17.

19.

Ex vivo IL-1 receptor type I expression in human CD4+ T cells identifies an early intermediate in the differentiation of Th17 from FOXP3+ naive regulatory T cells.

Raffin C, Raimbaud I, Valmori D, Ayyoub M.

J Immunol. 2011 Nov 15;187(10):5196-202. doi: 10.4049/jimmunol.1101742. Epub 2011 Oct 12.

20.

NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.

Redjimi N, Duperrier-Amouriaux K, Raimbaud I, Luescher I, Dojcinovic D, Classe JM, Berton-Rigaud D, Frenel JS, Bourbouloux E, Valmori D, Ayyoub M.

PLoS One. 2011;6(7):e22845. doi: 10.1371/journal.pone.0022845. Epub 2011 Jul 29.

21.

Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.

Hamaï A, Duperrier-Amouriaux K, Pignon P, Raimbaud I, Memeo L, Colarossi C, Canzonieri V, Perin T, Classe JM, Campone M, Jézéquel P, Campion L, Ayyoub M, Valmori D.

PLoS One. 2011;6(6):e21129. doi: 10.1371/journal.pone.0021129. Epub 2011 Jun 17.

22.

Expression of MAGE-A antigens is frequent in triple-negative breast cancers but does not correlate with that of basal-like markers.

Hamaï A, Memeo L, Colarossi C, Canzonieri V, Perin T, Ayyoub M, Valmori D.

Ann Oncol. 2011 Apr;22(4):986-7. doi: 10.1093/annonc/mdr038. Epub 2011 Mar 1. No abstract available.

PMID:
21363876
23.

Human RORγt+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors.

Valmori D, Raffin C, Raimbaud I, Ayyoub M.

Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19402-7. doi: 10.1073/pnas.1008247107. Epub 2010 Oct 20.

24.

Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1*0101 tetramers.

Ayyoub M, Pignon P, Dojcinovic D, Raimbaud I, Old LJ, Luescher I, Valmori D.

Clin Cancer Res. 2010 Sep 15;16(18):4607-15. doi: 10.1158/1078-0432.CCR-10-1485. Epub 2010 Jul 29.

25.

Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.

Ayyoub M, Dojcinovic D, Pignon P, Raimbaud I, Schmidt J, Luescher I, Valmori D.

Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7437-42. doi: 10.1073/pnas.1001322107. Epub 2010 Apr 5.

26.

Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.

Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Ayyoub M, Valmori D.

Clin Cancer Res. 2009 Jul 1;15(13):4467-74. doi: 10.1158/1078-0432.CCR-09-0582. Epub 2009 Jun 16.

27.

Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.

Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario JD Jr, Andrews C, Matsuzaki J, Valmori D, Ayyoub M, Frederick PJ, Beck A, Liao J, Cheney R, Moysich K, Lele S, Shrikant P, Old LJ, Odunsi K.

Cancer Res. 2009 Jul 1;69(13):5498-504. doi: 10.1158/0008-5472.CAN-08-2106. Epub 2009 Jun 2.

28.

Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t.

Ayyoub M, Deknuydt F, Raimbaud I, Dousset C, Leveque L, Bioley G, Valmori D.

Proc Natl Acad Sci U S A. 2009 May 26;106(21):8635-40. doi: 10.1073/pnas.0900621106. Epub 2009 May 13.

29.
30.

Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.

Leveque L, Deknuydt F, Bioley G, Old LJ, Matsuzaki J, Odunsi K, Ayyoub M, Valmori D.

J Immunother. 2009 Feb-Mar;32(2):101-8. doi: 10.1097/CJI.0b013e318195b59e.

PMID:
19238008
31.

IL-1beta and IL-2 convert human Treg into T(H)17 cells.

Deknuydt F, Bioley G, Valmori D, Ayyoub M.

Clin Immunol. 2009 May;131(2):298-307. doi: 10.1016/j.clim.2008.12.008. Epub 2009 Feb 11.

PMID:
19211307
32.

HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.

Bioley G, Guillaume P, Luescher I, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Valmori D, Ayyoub M.

Clin Cancer Res. 2009 Jan 1;15(1):299-306. doi: 10.1158/1078-0432.CCR-08-1747.

33.

Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.

Garcia Casado J, Janda J, Wei J, Chapatte L, Colombetti S, Alves P, Ritter G, Ayyoub M, Valmori D, Chen W, Lévy F.

Eur J Immunol. 2008 Jul;38(7):1867-76. doi: 10.1002/eji.200737923.

34.

Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs.

Tosello V, Odunsi K, Souleimanian NE, Lele S, Shrikant P, Old LJ, Valmori D, Ayyoub M.

Clin Immunol. 2008 Mar;126(3):291-302. doi: 10.1016/j.clim.2007.11.008. Epub 2007 Dec 31.

PMID:
18166500
35.

Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells.

Susumu S, Nagata Y, Ito S, Matsuo M, Valmori D, Yui K, Udono H, Kanematsu T.

Cancer Sci. 2008 Jan;99(1):107-12. Epub 2007 Nov 7.

36.

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, Angiulli F, Mears G, Vogel SM, Pan L, Jungbluth AA, Hoffmann EW, Venhaus R, Ritter G, Old LJ, Ayyoub M.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):8947-52. Epub 2007 May 15.

37.

Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals.

Godefroy E, Wang Y, Souleimanian NE, Scotto L, Stevanovic S, Chen YT, Valmori D, Ayyoub M.

Cancer Immunol Immunother. 2007 Aug;56(8):1183-92. Epub 2006 Dec 22.

PMID:
17186289
38.

Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen.

Valmori D, Lévy F, Godefroy E, Scotto L, Souleimanian NE, Karbach J, Tosello V, Hesdorffer CS, Old LJ, Jager E, Ayyoub M.

Clin Immunol. 2007 Feb;122(2):163-72. Epub 2006 Oct 24.

PMID:
17064965
39.

Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors.

Le Gal FA, Widmer VM, Dutoit V, Rubio-Godoy V, Schrenzel J, Walker PR, Romero PJ, Valmori D, Speiser DE, Dietrich PY.

J Invest Dermatol. 2007 Mar;127(3):622-9. Epub 2006 Oct 12.

40.

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

Jäger E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E, Ritter G, Jäger D, Panicali D, Hoffman E, Pan L, Oettgen H, Old LJ, Knuth A.

Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14453-8. Epub 2006 Sep 19.

41.

Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content.

Ye SW, Wang Y, Valmori D, Ayyoub M, Han Y, Xu XL, Zhao AL, Qu L, Gnjatic S, Ritter G, Old LJ, Gu J.

J Clin Immunol. 2006 Sep;26(5):447-56. Epub 2006 Sep 12.

PMID:
16967323
43.

Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles.

Godefroy E, Scotto L, Souleimanian NE, Ritter G, Old LJ, Jotereau F, Valmori D, Ayyoub M.

Clin Immunol. 2006 Oct;121(1):54-62. Epub 2006 Jun 30.

PMID:
16814609
44.

Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses.

Chapatte L, Ayyoub M, Morel S, Peitrequin AL, Lévy N, Servis C, Van den Eynde BJ, Valmori D, Lévy F.

Cancer Res. 2006 May 15;66(10):5461-8.

45.

Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells.

Valmori D, Qian F, Ayyoub M, Renner C, Merlo A, Gnjatic S, Stockert E, Driscoll D, Lele S, Old LJ, Odunsi K.

Clin Cancer Res. 2006 Jan 15;12(2):398-404. Erratum in: Clin Cancer Res. 2006 Mar 1;12(5):1656. Gjnatic, Sacha [corrected to Gnjatic, Sacha].

46.

A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.

Ayyoub M, Souleimanian NE, Godefroy E, Scotto L, Hesdorffer CS, Old LJ, Valmori D.

Clin Immunol. 2006 Feb-Mar;118(2-3):188-94. Epub 2005 Dec 20.

PMID:
16368270
47.

Tinkering with nature: the tale of optimizing peptide based cancer vaccines.

Michielin O, Blanchet JS, Fagerberg T, Valmori D, Rubio-Godoy V, Speiser D, Ayyoub M, Alves P, Luescher I, Gairin JE, Cerottini JC, Romero P.

Cancer Treat Res. 2005;123:267-91. Review. No abstract available.

PMID:
16211875
48.

Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals.

Valmori D, Souleimanian NE, Hesdorffer CS, Old LJ, Ayyoub M.

Clin Immunol. 2005 Nov;117(2):161-7. Epub 2005 Aug 15.

PMID:
16103015
49.

A peripheral circulating compartment of natural naive CD4 Tregs.

Valmori D, Merlo A, Souleimanian NE, Hesdorffer CS, Ayyoub M.

J Clin Invest. 2005 Jul;115(7):1953-62.

50.

Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses.

Valmori D, Souleimanian NE, Hesdorffer CS, Ritter G, Old LJ, Ayyoub M.

Clin Immunol. 2005 Oct;117(1):24-30.

PMID:
15994128

Supplemental Content

Loading ...
Support Center